title: Diet drugs Belviq and Qsymia receive FDA approval: what dentists need to know.
authors.affiliation: Department of Oral Craniofacial Biological Sciences, Dental School, University of Maryland, Baltimore, USA.
authors.forename: Richard L
authors.initials: RL
authors.lastname: Wynn
mesh_terms: D019440:Anti-Obesity Agents / Q000009:adverse effects / Q000494:pharmacology*; D001552:Benzazepines / Q000009:adverse effects / Q000494:pharmacology*; D017277:Drug Approval; D004338:Drug Combinations; D005632:Fructose / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology; D006801:Humans; D010645:Phentermine / Q000009:adverse effects / Q000494:pharmacology*; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D019440:Anti-Obesity Agents; D001552:Benzazepines; D004338:Drug Combinations; C576188:Qsymia; D005632:Fructose; C506658:lorcaserin; D010645:Phentermine